The FDA has approved Wegovy (semaglutide) tablets, the first oral GLP-1 receptor agonist for the treatment of obesity.

Real-time continuous glucose monitoring (rt-CGM) reduced large-for-gestational-age (LGA) births in women with gestational diabetes.

Topline data were announced from a phase 3 trial evaluating ersodetug in patients aged 3 months to 45 years with congenital hyperinsulinism.

Higher body dissatisfaction was linked to more severe eating disorder, depressive symptoms in monozygotic and dizygotic twin difference analyses. HealthDay News — Body dissatisfaction may causally ...

Sports injuries do not occur more often during menstruation, but those sustained during menstruation have a significantly higher burden.

The FDA approved Lerochol, a monthly PCSK9 inhibitor, for adults with hypercholesterolemia to reduce LDL-C levels alongside diet and exercise.

Giredestrant shows significant improvement in iDFS in patients with early-stage, HR-positive, HER2-negative breast cancer.

Youth-onset type 2 diabetes (T2D) can be characterized into reproducible clusters that demonstrate differential response to treatments and risk of complications, but cluster membership does not ...

Inhaled Technosphere insulin (TI) did not meet the prespecified noninferiority margin for HbA1c compared with subcutaneous rapid-acting analog (RAA) insulin among youth with diabetes over 26 weeks.

WHO reports that nearly 30 million children were under-protected against measles in 2024. with only 84% receiving a first vaccine dose. HealthDay News — Between 2000 and 2024, global measles deaths ...

Drugmaker Novo Nordisk announced that an oral version of semaglutide, the active ingredient in Ozempic and Wegovy, was safe but ultimately failed to slow memory or cognitive decline in 2 Phase 3 ...